Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 3/20 | 0.43 |
| ▸ | RHEB | Q15382 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 5/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.38 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29237678 | 1.00 | SNCA (0.43) | SNCARHEBPPARDKDM4EALDH1A1 | |
| SCHEMBL30967906 | 0.87 | TNKS (0.48) | RHEBPPARDBRD4 | |
| SCHEMBL29237386 | 0.87 | TNKS (0.48) | RHEBPPARDBRD4 | |
| SCHEMBL31108617 | 0.86 | L3MBTL1 (0.44) | RHEBKDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL29237722 | 0.82 | F10 (0.56) | RHEB | |
| SCHEMBL30217325 | 0.82 | F10 (0.56) | RHEB | |
| SCHEMBL30967902 | 0.77 | NPC1 (0.47) | KDM4EALDH1A1HDAC8NPC1RAB9A | |
| SCHEMBL29237301 | 0.77 | NPC1 (0.47) | KDM4EALDH1A1HDAC8NPC1RAB9A | |
| SCHEMBL31108471 | 0.75 | RHEB (0.48) | RHEBPPARDALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL29338297 | 0.75 | KDM4E (0.38) | SNCARHEBKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279220-A1 | INDOLE COMPOUNDS AND METHODS OF USE | SIONNA THERAPEUTICS INC. | 2024-08-22 | — | — | US | disclosed |
| CN-118201919-A | Indole compounds and methods of use | 健赞公司 | 2024-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279220-A1 | INDOLE COMPOUNDS AND METHODS OF USE | CFTR, INMT, IDO1 | SNCA 1374/4885RHEB 3259/4885PPARD 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.